Stratasys (NASDAQ: SSYS), a global leader in applied additive technology solutions, unveiled BioMimics – an advanced capability to 3D print medical models engineered to meet demands of leading hospitals, researchers and medical device manufacturers. Offered initially in North America as a service through Stratasys Direct Manufacturing, BioMimics provides realistic, functionally accurate 3D printed replicas of complex anatomical structures – empowering more effective medical training, education and advanced device testing.
Eliminating restrictions associated with training, research and testing on animal, mannequin, or cadaver models – BioMimics effectively mirrors the intricacies of both soft tissue and hard bones through multi-material 3D printing. Using Stratasys’ PolyJet 3D printing technology and new materials and software, organizations can create specific 3D printed models that match what professionals encounter during live medical scenarios. Additionally, OEMs can gain real-time feedback on device performance in realistic environments – prior to actual deployment.
“Testing innovative medical devices, teaching principles of surgery, providing continuing medical education, and demonstrating new products to clinicians all require ‘bench-top’ models that simulate human bodies and diseases. Much like simulation and co-piloting builds expertise for pilots, medical practitioners hone skills throughout their careers to provide exceptional care,” said Scott Rader, GM of Healthcare Solutions at Stratasys. “The challenges of today’s solutions include animal models that only approximate human anatomy, and cadavers that don’t retain the live-tissue feel and often lack targeted pathology.”
Rader continued, “BioMimics is a revolution in medical modeling, capitalizing on advanced 3D printing techniques for clinically accurate representations of complex human anatomies – from microscopic patterns of tissue to replicating soft to hard texture of body structures. Armed with unmatched realism of BioMimics, researchers, educators and manufacturers can use the tools to prove out new ideas before clinical trials, and demonstrate innovations to the skilled physicians who rely on them.”
Available today in North America through Stratasys Direct Manufacturing, BioMimics is initially designed to model the complexities of heart and bone structures – with vascular anatomies expected in early 2018. Engineered alongside the industry’s top researchers and manufacturers, the service empowers customers to either capitalize on a variety of existing BioMimics models, or design enhanced anatomical structures that match distinct clinical requirements.
“The Jacobs Institute has been using Stratasys 3D printing solutions to replicate vascular anatomy for many years. The BioMimics capabilities Stratasys has now developed enable a level of biomechanical realism and clinical sophistication not previously available in any vascular model,” said Dr. Adnan Siddiqui, Chief Medical Officer at Jacobs Institute, Vice-Chairman and Professor of Neurosurgery at University of Buffalo Neurosurgery.
“BioMimics will enhance medical innovation in vascular disease by enabling improved pre-clinical validation of new devices and clinically realistic training simulators.”
“As one of the top research and pediatrics hospitals in Canada, SickKids is committed to unprecedented innovation to positively impact the well-being of children around the world. We have developed new training programs through 3D printing that allow surgeons to practice procedures on replicas of real patient’s pathology,” said Shi-Joon Yoo, MD, PhD, Cardiac Radiologist at the Hospital for Sick Children and Professor of Medical Imaging and Pediatrics at University of Toronto. “BioMimics enhances the realism and clinical validity of the models even further – allowing the surgeons to develop the techniques and skills that will translate into live patient cases.”
Stratasys Direct Inc.
www.stratasys.com
www.stratasys.com/medical/biomimics
